Mr. Gill is currently the CFO of EndoChoice, a medical device company which provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal diseases. Prior to joining EndoChoice, he served as CFO of INC Research, a clinical research organization.
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
Spine device company stock report — 5 key companies
Smith & Nephew’s 2014 revenue up 2%: 10 things to know
8 key points on Misonix’s 2Q financial report — sales up 36%
